AtheroGenics Inc. reported at the European Society of Cardiology Congress 2007 that its experimental drug AGI-1067 shows some promise in fighting diabetes.
The drug, an oral anti-diabetic compound with anti-inflammatory and antioxidant properties, in March failed its trial as a heart medication.
Atlanta-based AtheroGenics (NASDAQ: AGIX) said its data shows at 12 months, AGI-1067 "significantly lowered" levels of glycated hemoglobin A1c, a commonly used measure of glycemic control.
The data showed a reduction of 59 percent in the development of new onset diabetes in patients with impaired fasting glucose, a condition which is a precursor to diabetes.
In patients with diabetes, treatment with AGI-1067 also demonstrated a 22 percent reduction in hard cardiovascular events of cardiovascular death, cardiac arrest, myocardial infarction and stroke, the company said.
"We believe that the unique mechanism of action for AGI-1067 may provide multiple therapeutic benefits for patients with diabetes," said Dr. Rob Scott, AtheroGenics chief medical officer. "AtheroGenics is focused on the ANDES clinical trial to confirm the beneficial effect of AGI-1067 on glycemic control as the next step in clinical development for the agent."
No comments:
Post a Comment